| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/14/2001 | WO2001041786A1 METHODS TO STIMULATE INSULIN PRODUCTION BY PANCREATIC β-CELLS |
| 06/14/2001 | WO2001041785A2 Enzyme treatment for infection |
| 06/14/2001 | WO2001041784A1 Methods and compositions for use in the treatment of filovirus mediated disease conditions |
| 06/14/2001 | WO2001041783A1 Methods and compositions for treatment of inflammatory disease |
| 06/14/2001 | WO2001041782A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 06/14/2001 | WO2001041781A2 Id protein inhibitors for treating ocular diseases |
| 06/14/2001 | WO2001041780A2 Use of an immunosuppressant for increasing an antifugal activity of a lipopeptide |
| 06/14/2001 | WO2001041779A2 Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| 06/14/2001 | WO2001041777A1 Calcium sorbefacients and process for producing the same |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041741A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | WO2001041704A2 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | WO2001041534A2 Pseudomycin phosphate prodrugs |
| 06/14/2001 | WO2001030811A3 Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis |
| 06/14/2001 | WO2001027244A9 Body member with adjustable stiffness and frequency |
| 06/14/2001 | WO2001018041A3 Flint proteins and formulations thereof |
| 06/14/2001 | WO2001018040A3 Use of leptin in inhibition of endothelial cell proliferation |
| 06/14/2001 | WO2001018036A3 Methods and reagents for regulating gene expression |
| 06/14/2001 | WO2001016168A3 Induction of programmed cell death by n5 gene |
| 06/14/2001 | WO2001012789A3 APOLIPOPROTEIN B mRNA-SPECIFIC RIBOZYME |
| 06/14/2001 | WO2001009189A3 Compositions and methods for the treatment of tumors |
| 06/14/2001 | WO2001008697A3 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001000829A8 Human endogenous retrovirus in breast cancer |
| 06/14/2001 | WO2001000812A3 22012, a novel human carboxypeptidase |
| 06/14/2001 | WO2000078358A3 Hyaluronic acid microspheres for sustained gene transfer |
| 06/14/2001 | WO2000068267A9 LOW-DOSE IL-1β-INDUCED PHOTORECEPTOR CELL RESCUE WITHOUT RETINAL DYSPLASIA |
| 06/14/2001 | WO2000068255A3 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| 06/14/2001 | WO2000035950A9 Reagents and methods useful for detecting diseases of the breast |
| 06/14/2001 | WO2000032631A3 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof |
| 06/14/2001 | WO1998037194A9 Ell2, a member of an ell family of rna polymerase ii elongation factors |
| 06/14/2001 | WO1998031818A9 Tace-like and matrilysin-like polypeptides |
| 06/14/2001 | US20010003750 Used as research tools in pharmacological, diagnostic studies and treatment of diseases in mammals in which 1L-beta-protease activity is implicated; antiinflammatory agent |
| 06/14/2001 | US20010003743 Consisting of a polynucleotide encoding the polypeptide comprising amino acid 1 to 578 of a specific amino acid sequence, a polynucleotide capable of hybridizing to above polynuceotide and a fragment of both polynucleotides |
| 06/14/2001 | US20010003742 Antilipemic formulation |
| 06/14/2001 | US20010003740 Method of treating thrombocytopenic purpura and hemolytic uremic syndrome |
| 06/14/2001 | US20010003739 Systemic administration of a therapeutic preparation |
| 06/14/2001 | US20010003589 Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid |
| 06/14/2001 | CA2396739A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | CA2396513A1 Pseudomycin phosphate prodrugs |
| 06/14/2001 | CA2395417A1 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 06/14/2001 | CA2394970A1 Novel steroid-activated nuclear receptors and uses therefor |
| 06/14/2001 | CA2394928A1 Amphiphilic polymers and polypeptide conjugates comprising same |
| 06/14/2001 | CA2394917A1 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | CA2394303A1 Interferon-alpha induced gene |
| 06/14/2001 | CA2393960A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393859A1 Apoptin-associating protein |
| 06/14/2001 | CA2393763A1 Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 06/14/2001 | CA2393738A1 Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393730A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | CA2393725A1 Histone deacetylase-8 proteins, nucleic acids, and methods of use |
| 06/14/2001 | CA2393688A1 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393587A1 Use of an immunosuppressant for increasing an antifungal activity of a lipopeptide |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393526A1 Nucleic acid delivery system |
| 06/14/2001 | CA2393463A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | CA2393332A1 Novel human kinase proteins and polynucleotides encoding the same |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392742A1 T1 receptor-like ligand ii and uses thereof |
| 06/14/2001 | CA2392740A1 Il-6 like polynucleotides, polypeptides, and antibodies |
| 06/14/2001 | CA2392568A1 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | CA2391944A1 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/14/2001 | CA2390676A1 Method of testing remedy or preventive for hyperlipemia |
| 06/14/2001 | CA2390093A1 Extracellular matrix and cell adhesion molecules |
| 06/14/2001 | CA2383001A1 Methods for introducing genes into mammalian subjects |
| 06/13/2001 | EP1106691A1 Apoptin-associating protein |
| 06/13/2001 | EP1106690A2 Polynucleotide encoding autoantigens associated with endometriosis |
| 06/13/2001 | EP1106686A1 Artiodactyl epimorphine |
| 06/13/2001 | EP1106626A1 Process for the preparation of regular glycopeptides |
| 06/13/2001 | EP1106625A1 Rhesus D specific peptide sequences |
| 06/13/2001 | EP1106624A1 5-membered ring compounds |
| 06/13/2001 | EP1106606A2 N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists |
| 06/13/2001 | EP1106183A2 Antibodies to erbB2 and their therapeutic uses |
| 06/13/2001 | EP1106182A1 Blood sugar level controlling agent |
| 06/13/2001 | EP1106181A1 Nutritional compositions for preventing or treating hyperlipoproteinemia |
| 06/13/2001 | EP1105738A1 Assays, methods and means for modulating nuclear localisation |
| 06/13/2001 | EP1105734A2 Homer interacting proteins |
| 06/13/2001 | EP1105518A1 USE OF mCRP FOR DELIVERY OF MATERIALS INTO CELLS |
| 06/13/2001 | EP1105513A2 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 06/13/2001 | EP1105506A1 Adenoviral vectors encoding erythropoietin and their use in gene therapy |
| 06/13/2001 | EP1105505A2 Compound and method for the prevention and/or the treatment of allergy |
| 06/13/2001 | EP1105504A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 06/13/2001 | EP1105503A2 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGCALPHA1/BETA1) |
| 06/13/2001 | EP1105501A2 Tpl-2/cot kinase and methods of use |
| 06/13/2001 | EP1105494A2 Drug targets in candida albicans |
| 06/13/2001 | EP1105492A1 Cloning of basb023 antigen from moraxella catarrhalis |
| 06/13/2001 | EP1105488A2 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
| 06/13/2001 | EP1105485A1 Human il-1 epsilon dna and polypeptides |
| 06/13/2001 | EP1105483A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 06/13/2001 | EP1105482A2 Genes that regulate hematopoietic blood forming stem cells and uses thereof |
| 06/13/2001 | EP1105481A2 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use |
| 06/13/2001 | EP1105480A1 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
| 06/13/2001 | EP1105479A2 Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105477A1 Dcr5, a bmp-binding protein, and applications thereof |
| 06/13/2001 | EP1105476A1 Pharmaceutical composition for treating or preventing diabetes or cancer, or the waardenburg syndrome |
| 06/13/2001 | EP1105475A1 Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia |
| 06/13/2001 | EP1105467A1 USE OF MODIFIED LYSOZYME c TO PREPARE MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES |